The most common adverse pregnancy outcome was eclampsia/pre-eclampsia, the prevalence of which was 8.4% in both cohorts.

The Food and Drug Administration (FDA) announced that it has accepted the New Drug Application (NDA) for UGN-102 for intravesical solution for the treatment of low-grade intermediate-risk non-muscle ...

Obesity directly affects kidney health and influences chronic kidney disease (CKD) risk and progression through contributing diseases such as type 2 diabetes and hypertension.

Nine statements developed, including performing 4 or more versus 3 or fewer needle passes in suspected malignant disease.

Of the about one-third receiving stimulant medication, 71.5% had difficulty filling prescription due to unavailability.

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...

Madison Olexson is a medical student at St. George’s University School of Medicine in Grenada, West Indies. Stephen Schleicher, MD, is director of the DermDox Dermatology Centers, associate ...

Glucagon-like peptide 1 receptor agonist prescription linked to reduction in risk for suicidal ideation or attempts ...

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

In subsequent dose-finding study, numerically greater reductions seen in fatigue, cognitive dysfunction scores with 40 to 45mg/day.